Location History:
- Harlow, GB (1998)
- Sawbridgeworth, GB (2000 - 2007)
Company Filing History:
Years Active: 1998-2007
Title: Beatrice Le Bourdelles: Innovator in GABA Receptor Research
Introduction
Beatrice Le Bourdelles is a notable inventor based in Sawbridgeworth, GB. She has made significant contributions to the field of neuroscience through her research on GABA receptors. With a total of 4 patents to her name, her work has implications for the development of new medicaments.
Latest Patents
Among her latest patents is the invention related to the "Delta subunit of human GABAA receptor." This invention involves the cloning of novel cDNA sequences encoding the α and δ receptor subunits of the human GABA receptor. It also includes the development of stably co-transfected eukaryotic cell lines capable of expressing a human GABA receptor, which comprises at least one of the novel α and δ receptor subunits. These cell lines are intended for use in screening and designing medicaments that act upon the human GABA receptor. Another significant patent is for the "Human α4 receptor subunit of the GABA-A receptor." This invention provides nucleotide sequences encoding the α and δ subunits of the human GABA receptor, along with preparations of receptor subunit proteins and methods for their preparation.
Career Highlights
Beatrice has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Merck Sharpe & Dohme Corp. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of neuroscience.
Collaborations
Throughout her career, Beatrice has collaborated with esteemed colleagues such as Paul John Whiting and Janice Ann Myers. These collaborations have further enriched her research and innovation in the field.
Conclusion
Beatrice Le Bourdelles stands out as an influential inventor in the realm of GABA receptor research. Her patents and collaborations reflect her commitment to advancing medical science and developing new therapeutic options.